Uruguay|Chinese vaccines providing promising solution to the pandemic: roundup safety|Egypt|of|aged|Chinese|Daily|a

When the COVID-19 pandemic still rages on with many countries and regions in dire need of vaccines, CoronaVac vaccine developed by Sinovac has been widely supplied across the world, demonstrating encouraging results in the global fight against the virus.
To ease the bottleneck of the production capacity and reach broader recipients, China has cooperated with eight countries to manufacture vaccines locally.

文章图片

Screenshot shows the article published on Daily News Egypt.
Egypt’s Prime Minister Mostafa Madbouly was cited as saying that the country have already produced one million doses of the Sinovac vaccine domestically, according to a July 5 article from local media Daily News Egypt.
The production line in Egypt marks the first instance of China working with an African country in vaccine manufacture. It’s expected to benefit the neighboring African and Middle Eastern countries after meeting Egypt’s own needs.
New evidence also emerged to reaffirm the safety and high efficacy of the vaccine developed by Sinovac.

文章图片

A woman receives a jab of China's Sinovac COVID-19 vaccine in Montevideo, Uruguay, March 1, 2021. (Photo by Nicolas Celaya/Xinhua)
Last month, a statement released by Uruguay’s Ministry of Public Health said the Sinovac vaccine reduced COVID-19 infections and deaths among Uruguayan adults. The real-world data showed the shots cut deaths by 95.3 percent among the vaccinated population aged 18 to 49, and by 95.2 percent among those aged 50 to 69. Meanwhile, it was 94 percent effective at preventing intensive care admissions.
As children and adolescents are always a key group of concern in vaccination drive, researchers have confirmed the safety and efficacy of CoronaVac for children as young as three in the early stage human trials.

文章图片

Screenshot shows the paper published on The Lancet.
“CoronaVac was well tolerated and safe and induced humoral responses in children and adolescents aged 3–17 years,” noted a June 28 paper published on The Lancet.
In the trial, a total of 552 young participants were given two doses of vaccine from Sinovac 28 days apart. Among the various age groups, more than 96 percent of trial participants were found to develop antibodies against the coronavirus in initial studies.
In terms of real-world application, Indonesia has recommended Sinovac vaccine for children aged 12 to 17, as Reuters reported June 28.
“The country seeks to extend inoculations amid a surge in infections,” said the article, “Task Force data shows children aged 0-18 account for 12.6 percent of Indonesia's total COVID-19 infections.”
【Uruguay|Chinese vaccines providing promising solution to the pandemic: roundup】Vaccines are key to curb the pandemic. Globally, as of 5 July 2021, more than 183 million cases of COVID-19 were confirmed, including nearly 4 million deaths. According to the latest data from WHO, a total of 298 million vaccine doses have been administered worldwide to date.
When the whole world is in a race between infection and injection, Chinese vaccines serve as a promising solution to conquer the pandemic for the easy accessibility, safety and high efficacy.
[责任编辑: WXL ]

以上关于本文的内容，仅作参考！温馨提示：如遇专业性较强的问题（如：疾病、健康、理财等），还请咨询专业人士给予相关指导!

「辽宁龙网」www.liaoninglong.com小编还为您精选了以下内容，希望对您有所帮助：